Health Innovation

For the first time, researchers at the Centre for Proton Therapy at PSI have tested ultrafast, high-dose irradiation with protons. The new, experimental FLASH technique could revolutionise radiation therapy for cancer.

At PSI, researchers are screening molecule fragments to see if these bind to important proteins of the coronavirus SARS-CoV-2 and thus have the potential to disable it. They are hoping the many individual pieces of information will yield an answer as to what an effective drug might look like.

SARS-CoV-2 might be transmitted via aerosols, that is, through the air. Researchers point this out in the journal Clinical Infectious Diseases. André Prévôt from PSI co-signed the publication. In this interview, he explains which precautionary measures he recommends.

Frankfurt scientists identify a possible weakness of the SARS-CoV-2 virus. They carried out part of their measurements at PSI's Swiss Light Source SLS. The research results are published this week in the scientific journal Nature.

In the service of health, scientists at the Paul Scherrer Institute PSI work with radionuclides and develop agents to treat cancer and to detect tumours. Their research provides support to hospitals and is of great interest to Swiss industry.

Radionuclides open up new options for treating cancer. Christian Rüegg, head of the Research with Neutrons and Muons Division at PSI, explains the significance of the Swiss Spallation Neutron Source SINQ at PSI.

At the neutron source SINQ, PSI researchers are producing special radionuclides that aid in the development of new and more effectively targeted cancer therapies. In this they collaborate closely with the clinics in the surrounding area.

Proton therapy is time-consuming and more costly than conventional radiation therapy, but its accuracy in targeting tumours is unsurpassed. An interview with Damien Weber, head of the Centre for Proton Therapy at PSI.

At PSI, cancer patients receive a therapy that is unique in Switzerland. Bombardment with protons wipes out cancer cells  –  and does so more precisely than with any other form of irradiation.

Researchers at the Paul Scherrer Institute PSI, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the development of an active substance against the metastasis of certain cancers. Using the Swiss Light Source SLS, they deciphered the structure of a receptor that plays a crucial role in the migration of cancer cells.

Researchers at the Paul Scherrer Institute PSI have an important part of the regulatory cycle that is involved in the formation and degradation of the cytoskeleton. Among other things, they have watched molecular scissors at work.

Researchers at the Paul Scherrer Institute PSI have elucidated an important part of a siganalling pathway that transmits information through the cell membrane into the interior of a cell. This exists in all mammals and plays an important role, among other things, in the regulation of the heartbeat. The new findings could lead to new therapies.

At PSI, Beate Timmermann built up a programme providing proton therapy for children with cancer at the same time she was raising her own son. Today she is head of the Clinic for Particle Therapy at the West German Proton Therapy Centre in Essen (WPE) and is considered one of the most accomplished experts in this field.

A radioactive agent, developed at the Paul Scherrer Institute PSI to fight an especially malignant form of thyroid cancer, has the potential to become a blockbuster drug. Due to its structure, it might also be able to dock onto cells of other tumours and destroy them with its radiation. The Lausanne-based biopharmaceutical company Debiopharm wants to further develop the PSI agent to the point where it is approved as a drug. Debiopharm and PSI have now created the contractual basis for this.

For the development of new medicinal agents, accurate knowledge of proteins is crucial. In a pilot experiment, researchers have now, for the first time, used the X-ray free-electron laser SwissFEL of PSI for the examination of protein crystals.

Gebhard Schertler is head of the research division Biology and Chemistry at the Paul Scherrer Institute PSI and professor for Structural Biology at ETH Zurich. In this interview he talks about biological research at PSI and the future of drug development.

Researchers from the Paul Scherrer Institute PSI, the University of Basel and Roche have used neutron imaging to investigate why cool storage is crucial for syringes pre-filled with a liquid medication.

The 16th of May is the International Day of Light. The research carried out with light at PSI enables advances in biology and pharmacology and also promotes the development of new materials for data storage and new technologies for personalised medicine.

With proton therapy, certain tumours can be irradiated with exceptional precision – while, the surrounding healthy tissue is optimally protected. In Switzerland, this kind of radiation therapy is only possible at PSI. In a joint project with the University Hospital Zurich and the University of Zurich, PSI has expanded its capacity with a state-of-the-art treatment facility: the new, 270-ton Gantry 3.